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Background: Oxytocin is known for its capacity to facilitate social bonding, reduce anxiety and for its actions on
the stress hypothalamopituitary adrenal (HPA) axis. Since oxytocin can physiologically suppress activity of the HPA
axis, clinical applications of this neuropeptide have been proposed in conditions where the function of the HPA
axis is dysregulated. One such condition is major depressive disorder (MDD). Dysregulation of the HPA system is the
most prominent endocrine change seen with MDD, and normalizing the HPA axis is one of the major targets of
recent treatments. The potential clinical application of oxytocin in MDD requires improved understanding of its
relationship to the symptoms and underlying pathophysiology of MDD. Previous research has investigated potential
correlations between oxytocin and symptoms of MDD, including a link between oxytocin and treatment related
symptom reduction. The outcomes of studies investigating whether antidepressive treatment (pharmacological and
non-pharmacological) influences oxytocin concentrations in MDD, have produced conflicting outcomes. These
outcomes suggest the need for an investigation of the influence of a single treatment class on oxytocin
concentrations, to determine whether there is a relationship between oxytocin, the HPA axis (e.g., oxytocin and
cortisol) and MDD. Our objective was to measure oxytocin and cortisol in patients with MDD before and following
treatment with selective serotonin reuptake inhibitors, SSRI.
Method: We sampled blood from arterial plasma. Patients with MDD were studied at the same time twice;
pre- and post- 12 weeks treatment, in an unblinded sequential design (clinicaltrials.govNCT00168493).
Results: Results did not reveal differences in oxytocin or cortisol concentrations before relative to following SSRI
treatment, and there were no significant relationships between oxytocin and cortisol, or these two physiological
variables and psychological symptom scores, before or after treatment.
Conclusions: These outcomes demonstrate that symptoms of MDD were reduced following effective treatment
with an SSRI, and further, stress physiology was unlikely to be a key factor in this outcome. Further research is
required to discriminate potential differences in underlying stress physiology for individuals with MDD who respond
to antidepressant treatment, relative to those who experience treatment resistance.
Keywords: Major depressive disorder, Oxytocin, Cortisol, Hypothalamopuitary adrenal axis, SSRI* Correspondence: ckeating@swin.edu.au
1Monash Alfred Psychiatry Research Centre, Central Clinical School, Monash
University and The Alfred, Melbourne, Australia
2Brain and Psychological Sciences Research Centre, Swinburne University of
Technology, Hawthorn, Australia
Full list of author information is available at the end of the article
© 2013 Keating et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Keating et al. BMC Psychiatry 2013, 13:124 Page 2 of 7
http://www.biomedcentral.com/1471-244X/13/124Background
Oxytocin is a neuropeptide that is synthesised in the
supraoptic (SON) and paraventricular (PVN) nuclei of
the hypothalamus. It is released into the brain via dis-
tributed oxytocinergic pathways and oxytocin receptors
are located in various socially relevant and stress-
sensitive brain regions [1]. This neuropeptide can facili-
tate maternal-infant attachment and pair-bond formation
in a variety of mammals [2-4], as well as decrease anxiety
and stress [5] when centrally administered [6]. Oxytocin is
also released in response to acute psychogenic stressors in
mammals [6,7].
Clinically, oxytocin has been shown to facilitate
improved social communication behaviour in humans
(e.g., eye contact, nonverbal positive behaviour and
self-disclosure). In an investigation involving healthy
controls, oxytocin compared with placebo reduced couple
conflict (improved social communication) and reduced
cortisol concentrations [8]. Multiple investigations have
also demonstrated the therapeutic application of oxytocin
for anxiety symptoms. For example, oxytocin has been
shown to enhance the buffering effect of social support
on stress responsiveness [9]. Oxytocin or placebo was
administered to healthy controls prior to exposure to
the Trier Social Stress Test (TSST) in the presence of
participants’ best friend or no social support [9]. Compared
to placebo, those administered oxytocin in the context
of social support experienced increased calmness and
decreased anxiety during the TSST, and showed the
lowest salivary free cortisol concentrations [9]. In
addition, in patients with social anxiety disorder, oxytocin
compared to placebo was associated with improved
positive evaluations of appearance and speech performance
as exposure treatment sessions progressed [10]. These
findings suggest that oxytocin can reduce symptoms of
anxiety which is likely, due in part, to attenuating the
activity of the HPA axis [8]. Although oxytocin can reduce
anxiety and attenuate activity of the hypothalamo-
pituitary adrenal (HPA) axis, [5,11] the precise mechanisms
by which this occurs are not yet well defined.
These findings suggest the possibility that oxytocin
may be of clinical relevance to disorders associated with
psychosocial impairment, anxiety and dysregulation of
the HPA axis. Individuals with major depressive disorder
(MDD) often experience difficulties in interpersonal
relationships, and social isolation. Furthermore, up to
60% of patients with MDD experience elevated activity
of the HPA-axis [12]. Dysregulation of the HPA system
is reportedly the most prominent endocrine change seen
in MDD and normalizing the HPA axis is one target of
recent treatment developments [13-15].
Several lines of evidence support that the oxytocin system
is altered in MDD. For example, a small sample of patients
with MDD (n = 3) showed a 23% increase in oxytocinneurons in the PON of the hypothalamus compared
with matched healthy controls [16]. It was concluded
that this increase may be linked to increased HPA axis ac-
tivity, commonly reported in patients with MDD [16]. In-
creased staining for oxytocin neurons has since been
demonstrated in other research [17]. Potential differences
in oxytocin, cortisol and arginine vasopressin concentrations
in patients with MDD (n = 11) compared with matched
healthy controls (n = 19) have also been investigated [18].
Results revealed increased oxytocin concentrations in indi-
viduals with MDD compared to healthy controls, whereas
no differences were observed in cortisol or arginine vaso-
pressin concentrations [18]. Elevated oxytocin concentra-
tions found in MDD is also consistent with evidence that
oxytocin mRNA levels are increased in depressed patients
(e.g., [16,18]).
The potential clinical relevance of oxytocin to MDD
has also been investigated. Plasma oxytocin concentra-
tions have been linked to the temperament dimension
of reward dependence (according to Temperament and
Character Inventory, TCI) in patients with MDD [19]. In
other research, although an association between perfor-
mance on neuropsychological testing and elevated basal
cortisol concentrations was demonstrated in MDD, no
association was found between performance and plasma
concentrations of oxytocin [20]. Significant correlations
have also been shown between oxytocin concentrations
and depressive symptoms in several studies involving
individuals with a diagnosis of: obsessive compulsive
disorder [21], fibromyalgia [22] and MDD [23,24].
A relationship between oxytocin and treatment out-
comes has also been investigated in MDD. In one study
involving patients with MDD or bipolar disorder, oxytocin
concentrations were not influenced by treatment (involving
either an SSRI, tricyclic antidepressant or electroconvulsive
therapy) [25]. These findings are in agreement with
previous results demonstrating no difference in cerebro-
spinal fluid oxytocin concentrations in medicated, symp-
tomatic individuals with MDD compared to healthy controls
[26]. Patients included in the study were taking heteroge-
neous treatments, however, (10 patients were treated
with a tricyclic antidepressant, two with a monoamine
oxidase inhibitor, two with lithium carbonate and one
with an antipsychotic [26]) which may have influenced
the outcomes.
Preclinical evidence indicates that oxytocin can influence
activity of the serotonin system, which may relate to
the antidepressant effects of SSRIs [27]. In a recent
study in mice, widespread expression of oxytocin receptor
containing cells were shown to be co-localised with
tryptophan hydroxylase-positive neurones in the raphe
nuclei [28]. Furthermore, intra-raphe infusion of oxytocin
increased serotonin release within the median raphe, a re-
sponse that was inhibited by serotonin 2A/2C receptor
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tonergic activity induced by oxytocin may underlie its
anxiolytic effects [28]. Given the use and effectiveness of
SSRI’s in MDD, these findings may also relate to their
antidepressant-like effects [27].
Further, evidence supports that the serotonin and
oxytocin systems may interact in the hypothalamus [29]. In
macaques, neuroanatomic evidence shows that the distri-
bution of serotonin transporter fibres follows the distribu-
tion of oxytocin cells in the hypothalamus in the
parvicellular, magnocellular, dorsal, and posterior subdivi-
sions of the paraventricular nuclei. In the supraoptic nuclei,
serotonin transporter fibers and oxytocin cells overlap in
the ventromedial subdivision and in the ‘capsular’ part
of the dorsolateral supraoptic nuclei [29]. Again, it has
been concluded that these findings provide neuroana-
tomical support that SSRIs’ therapeutic effects may be
mediated in part, through components of the oxytocin
system [29].
Although a number of pharmacological agents are
available to treat depression, at least 30-40% of patients
do not respond to these [30,31]. Therefore, there is a
major emphasis in psychiatry to uncover the underlying
aetiology of mood disorders, to be able to develop more
effective treatments [27]. In this respect, oxytocin may be
of therapeutic benefit in patients with MDD. The primary
aim of this study was to gain further understanding of the
role of oxytocin in the pathophysiology of MDD. Using an
open label treatment design we examined whether there
is a relationship between oxytocin concentrations and
symptoms of MDD and their resolution following (SSRI
Treatment. In a secondary aim, we intended to investigate
whether there is a clinically relevant relationship between
oxytocin and cortisol in relation to symptoms of MDD
and their resolution.Methods
Experimental design
In this study we extended an open label investigation of
SSRI treatment in patients with MDD [32]. Arterial
sampling was performed twice, first while patients were
untreated during a current depressive episode and then
following 12 weeks treatment with an SSRI. For each
patient, the samples were collected at the same time of
day. All patients involved in this study were treatment
responders. For all participants, 12 hours preceding
study visits, caffeine, alcohol and tobacco smoking were
prohibited. The research protocol was approved by
the Alfred Hospital ethics review committee. Written
informed consent was obtained from each subject
prior to the study.
The study included 16 participants with MDD (9 females,
7 males) ranging in age from 22 yrs to 71 yrs (mean ±SEM, 43.5 ± 3.3 years) who met DSM-IV criteria and
International Statistical Classification of Diseases, 10th
Revision (previously described in [32]). Patients were
either newly diagnosed or currently untreated after a
relapse and had not been receiving antidepressants or
benzodiazepines for at least 4 weeks prior to the study
(5 weeks if they had been receiving fluoxetine hydrochlor-
ide) (see Barton et al., 2008). Two females were taking
hormone-based contraceptives, two were postmenopausal,
and information was not available for the remaining four
individuals. Stage of menstrual cycle was not available.
Patients were initially screened via telephone and
interviewed by a psychiatrist (D.A.B.) using a structured
clinical interview (Mini International Neuropsychiatric
Interview, MINI). The 17-item Hamilton Depression Scale
(HAM-D), Spielberger’s State and Trait Anxiety Inventory
(STAI), and Beck Depression Inventory (BDI) were used
to assess severity and monitor response to treatment.
Patients were eligible for inclusion if they fulfilled criteria
for MDD on the MINI, had HAM-D and BDI scores of 18
or higher and were assessed as having MDD as the
primary illness at psychiatric interview. Patient selection
aimed to minimize psychiatric co-morbidity. The Anxiety
Disorders Interview Schedule for DSM-IV was used to
discriminate between anxiety disorders and for determining
the primary and secondary diagnosis based on the
participant’s responses and severity scores on measures of
symptoms. Clinical significance was defined as a score of
4 or higher on the 8-point Likert-type scale, where 2 is
mild, 4 is moderate, 6 is severe, and 8 is very severe.
Patients presenting with co-morbid panic or anxiety were
included if the primary diagnosis was depression and
any panic or anxiety was secondary to their depression.
Participants were excluded if they had coexisting heart
disease, diabetes, medicated hypertension, alcohol or
drug abuse or dependence, or infectious disease; had a
co-morbid psychotic disorder, eating disorder, mental
retardation, personality disorder, or epilepsy; or had a
current high suicide risk. Patients having previously
failed to respond to SSRI treatment at the maximum
tolerated dose for at least 4 weeks were excluded from
the study.
Within 10 days of confirming diagnosis of MDD, initial
research studies were performed. Patients then commenced
treatment with an SSRI which was determined on clinical
grounds in consult with the participant (12 received
citalopram hydrochloride, 2 received sertraline hydrochlo-
ride, 2 received fluoxetine). No structured psychotherapy
was provided to the patients in the context of the re-
search study, or external to it. Repeat research studies with
arterial blood sampling was performed after approximately
12 weeks of therapy. Patients were examined weekly for
the purposes of the study or more frequently if required
on clinical grounds (as previously described [32]).
Figure 1 HAM-D scores in patients with MDD, untreated and
following SSRI treatment.
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of more than 50% in HAM-D scores and remission as a
HAM-D score lower than 8.
Oxytocin cortisol radioimmunoassays
Arterial concentrations of oxytocin were measured
before and after SSRI treatment by radioimmunoassay
using Phoenix Pharmaceuticals Oxytocin RIA Kit (Belmont,
California, USA) [33]. There was 100% cross-reactivity of
the oxytocin antibody with oxytocin and no cross-reactivity
with arginine vasopressin. All samples were measured
in a single assay. Cortisol concentrations were measured
in plasma collected before and after SSRI treatment
using an extracted radioimmunoassay [34] using hydro-
cortisone (H-4001, Sigma Chemical Company, St Louis,
MO, USA) as standard. The assay utilized [3H]-cortisol
(Amersham Pharmacia Biotech UK, Buckinghamshire
HP, England) as tracer and a dichloromethane extraction
procedure with a mean (± SEM) recovery of 93.2 ± 2.8%.
All samples were measured in a single assay, which had a
sensitivity of 0.44 ng/ml.
Statistical analyses
We tested the normality of the distribution of oxytocin
data by conducting a Kolmogorov-Smirnov statistic. The
primary variable of interest, oxytocin, was not normally
distributed. Therefore, we conducted nonparametric
statistics: Mann–Whitney test, Wilcoxon sign ranked
test, and Spearmann’s rho correlations.
Wilcoxon ranks test was used to assess differences in
oxytocin and cortisol concentrations before (untreated)
compared to following (treated) SSRI therapy. Pairs of
dependent variables were: arterial oxytocin concentrations
(A1 and A2), cortisol concentrations (visit 1 and visit 2),
as well as psychopathology scores, HAMD (visit 1 and
visit 2), BDI-I (visit 1 and visit 2), STAI state (visit 1 and
visit 2) and STAI trait scores (visit 1 and visit 2).Figure 2 Arterial oxytocin concentrations in patients with MDD
untreated and following SSRI treatment (p > .05).Results
Symptoms of MDD and anxiety
Patients with MDD were moderately depressed with a
mean (±SEM) HAM-D score of 25.1 ± 1.0 and BDI score
of 28.8 ± 1.7. They also had high levels of trait anxiety
with a mean (±SEM) 62.1 ± 1.8 and of state anxiety
56.8 ± 2.9. Following therapy, patients showed a 50%
reduction (or more) in clinical symptoms (mean ± SEM):
HAM-D 6.6 ± 1.2 (Figure 1) and BDI 8.9 ± 1.4 and demon-
strated moderate to high anxiety symptoms (mean ± SEM):
trait anxiety 44.9 ± 3.1 and state anxiety 38.2 ± 2.5.
Oxytocin
There was no change in the plasma concentrations of
oxytocin following treatment with an SSRI (Figure 2).There occurred no difference in the response between
males and females.
Cortisol
The mean (±SEM) plasma concentrations of cortisol
(ng/ml) did not change significantly before (88.3 ± 6.8)
to following (84.3 ± 6.2) treatment with an SSRI (p > .05).
There occurred no difference in the response between
males and females.
Oxytocin, cortisol and psychopathology
There were no significant correlations between oxytocin
and cortisol, or each of oxytocin, and cortisol with
symptoms of MDD (p > .05).
Discussion
Our findings indicate that oxytocin concentrations in
patients with MDD are not influenced by effective
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agreement with previous research that has demonstrated
no change in serum oxytocin concentrations following
various antidepressant treatments (pharmacological and
ECT), in a sample that included both bipolar disorder
and MDD [25], it is contrary to some preclinical data.
For example, previous studies in rats showed that
antidepressant (SSRI) medication can increase concentra-
tions of oxytocin (e.g., [35]). Oxytocin mRNA expression
in the PVN and SON has been shown to increase following
stimulation via a variety of serotonin agonists (e.g., 1A, IB,
2A and 2C) [36]. In addition, both acute and chronic
(2 week) administration of intraperitoneal citalopram or
zimeldine (different antidepressants within the SSRI class)
resulted in increased plasma oxytocin secretion [35]. In a
recent study, a yellow fluorescent protein, Venus, was
placed under control of the regulatory region of the gene
encoding the oxytocin receptor in order to determine
the expression pattern of oxytocin receptors throughout
the brain. Widespread expression of oxytocin receptor
containing cells were observed in these mice, in particu-
lar, a large co-localisation of Venus with tryptophan
hydroxylase-positive neurons in the raphe nuclei [28].
Furthermore, intra-raphe infusion of oxytocin increased
serotonin release within the median raphe, which was
inhibited by serotonin 2A/C receptor antagonists. This
lead the authors to speculate that the increased serotonergic
activity induced by oxytocin may underlie its anxiolytic
effects [28] and given the use of SSRI’s in MDD, these
findings may also relate to their antidepressant-like effects
[27]. We have, however, previously shown a reduction in
serotonin turnover following SSRI therapy [32].
In our study, SSRIs were effective in treating symptoms
of MDD in these patients (e.g., at least 50% reduction in
symptoms following 12 weeks therapy). Although it is
accepted that the HPA axis is commonly dysregulated in
patients with MDD [12,13] the mechanisms are not
well understood and the direction of dysregulation
can furthermore vary. Nevertheless, sustained elevated
activity of the HPA axis following antidepressant therapy
has been previously linked to treatment resistance in
patients with MDD (e.g., [37,38]). Hence, a priori selecting
patients with a history of MDD that is resistant to
treatment (with a matched healthy control group at
baseline) may help to determine how dysregulation of
the HPA axis (including oxytocin) relates to the
pathophysiology of symptoms experienced by certain
patients, and whether the HPA axis may represent a
clinically relevant treatment target.
We did not show a change in the concentrations of
cortisol in patients with MDD in response to treatment
with SSRIs, suggesting that SSRIs did not significantly
impact activity of the HPA axis in order to resolve
symptoms. While measurements of cortisol and otherstress hormones are notoriously difficult to control as
the time of day, season, exercise, smoking, general health
and the immediate events right before sampling can
all affect biological measurement of cortisol [39], we
controlled for time of day and season, caffeine, alcohol
and tobacco smoking intake within 12 hours of study
visits, and general health (as described previously, [32]). A
limitation of the current study, however, is that hormones
were not sampled across the day, on each of the study
visits. Individuals with depression (compared with healthy
controls) often demonstrate abnormal diurnal rhythm of
cortisol with lower morning cortisol levels and higher
evening levels [40]. Nevertheless, The fact that our results
were in a small number of patients, and no differences in
cortisol concentrations were detected from before relative
to following treatment, attests to the robustness of our
sampling procedure. Meta-analyses suggest, however, that
MDD is associated with hypercortisolism at certain times
of the day [40,41], hence, future research efforts should
sample cortisol concentrations across the day.
In the current study, oxytocin concentrations in patients
with MDD ranged between 2 pg/mL and 69 pg/mL with
an overall mean of 8.52 pg/mL (untreated) and 8.72 pg/mL
(treated). These findings are in agreement with previ-
ous research [25]. Several other studies have reported oxy-
tocin concentrations that are significantly higher than
those of the current study, however, the majority of these
reports stem from observations in healthy populations.
For example, in a large cohort of women and men
(n = 323), oxytocin concentrations were averaged at
375.78 pg/mL [42]. Nevertheless, these concentrations
ranged from 51.4 pg/mL to 2752.3 pg/mL, which suggests
that in the general population, oxytocin concentrations
are variable. Hence, future research should include
comparison between patients and healthy control groups.Conclusions
In summary, this open label study presents data on
arterial oxytocin and cortisol concentrations in patients
with MDD before and following SSRI treatment. This
has extended research in several ways. We have shown
that oxytocin and cortisol concentrations in patients
with MDD were not influenced by a single class of
antidepressant treatment. This suggests that stress
physiology is unlikely to contribute in a key manner
to symptoms of MDD, or their resolution, for this group
of patients who experience effective relief of their
symptoms following SSRI therapy. It is well known
that elevated activity of the HPA axis can impair a re-
sponse to antidepressant treatment (including SSRIs).
Thus, to better understand the contribution of HPA axis
dysregulatoin to MDD, a priori selection of patients with
a history of MDD that is resistant to treatment, may
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